Interface between pharmacotherapy and genes in human obesity

Human Heredity

Volumn 75, Issue 2-4, 2013, Pages 116-126

  O'Connor, Annalouise ^a   Swick, Andrew G ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Obesity; Pharmacogenetics; Pharmacogenomics; Weight loss drugs

Indexed keywords

ABACAVIR; CLOPIDOGREL; EXENDIN 4; GI 181771; LORCASERIN; PHENTERMINE; PHENTERMINE PLUS TOPIRAMATE; PLACEBO; QYSMIA; RIMONABANT; SIBUTRAMINE; TETRAHYDROLIPSTATIN; UNCLASSIFIED DRUG; WARFARIN; ANTIOBESITY AGENT; CANNABINOID 1 RECEPTOR ANTAGONIST; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST;

ABDOMINAL PAIN; ABNORMAL FECES; ADIPONECTIN GENE; ALPHA 2A ADRENERGIC RECEPTOR GENE; ANXIETY; ARTHRALGIA; ARTICLE; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROVASCULAR ACCIDENT; CLEFT FACE; CONSTIPATION; DEPRESSION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DYSGEUSIA; FLATULENCE; GASTROINTESTINAL SYMPTOM; GENE; GENETIC VARIABILITY; GNB3 GENE; HEADACHE; HEART INFARCTION; HEART PALPITATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOGLYCEMIA; INSOMNIA; IRRITABILITY; MEDICATION COMPLIANCE; MENTAL DISEASE; NAUSEA; OBESITY; OILY STOOL; PARESTHESIA; PATIENT COMPLIANCE; PHARMACOGENOMICS; PNMT GENE; PULSE RATE; RHINOPHARYNGITIS; SEROTONIN TRANSPORTER GENE; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; SUICIDAL IDEATION; TACHYCARDIA; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT REDUCTION; XEROSTOMIA; ADIPOQ GENE; ADRA2A GENE; ENERGY BALANCE; LIFESTYLE MODIFICATION; META ANALYSIS (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SLC6A4 GENE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTI-OBESITY AGENTS; DRUG DISCOVERY; HUMANS; OBESITY; PHARMACOGENETICS; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84885003273     PISSN: 00015652     EISSN: 14230062     Source Type: Journal    
DOI: 10.1159/000349975     Document Type: Article

References (83)

1. World Health Organization: Obesity and Overweight. Fact Sheet No. 311, 2012.
2. Trust for America's Health: F as in Fat: How Obesity Threatens America's Future. Washington, DC, Trust for America's Health, 2011.
3. Wang Y, Beydoun MA, Liang L, Caballero B, Kumanyika SK: Will all Americans become overweight or obese? Estimating the progression and cost of the US obesity epidemic. Obesity (Silver Spring) 2008; 16: 2323-2330.
4. McPherson K, Marsh T, Brown M: Foresight Report. Tackling Obesities: Future Choices - Modelling Future Trends in Obesity and Their Impact on Health, ed 2. London, Government Office for Science, 2007.
5. Loos RJ: Genetic determinants of common obesity and their value in prediction. Best Pract Res Clin Endocrinol Metab 2012; 26: 211-226.
6. Dubern B, Clement K: Leptin and leptin receptor- related monogenic obesity. Biochimie 2012; 94: 2111-2115.
7. Sandholt CH, Hansen T, Pedersen O: Beyond the fourth wave of genome-wide obesity association studies. Nutr Diabetes 2012; 2:e37.
8. Loos RJ, Lindgren CM, Li S, Wheeler E, Zhao JH, Prokopenko I, et al: Common variants near MC4R are associated with fat mass, weight and risk of obesity. Nat Genet 2008; 40: 768-775.
9. Frayling TM, Timpson NJ, Weedon MN, Zeggini E, Freathy RM, Lindgren CM, et al: A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science 2007; 316: 889-894.
10. National Institutes of Health, National Heart, Lung, and Blood Institute, North American Association for the Study of Obesity: The Practical Guide: Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. NIH Publication No. 00-4084, 2000.
11. Ribisl PM, Gaussoin SA, Lang W, Bahnson J, Connelly SA, Horton ES, et al: Lifestyle intervention improves heart rate recovery from exercise in adults with type 2 diabetes: results from the Look AHEAD study. J Obes 2012; 2012: 309196.
12. Unick JL, Beavers D, Jakicic JM, Kitabchi AE, Knowler WC, Wadden TA, et al: Effectiveness of lifestyle interventions for individuals with severe obesity and type 2 diabetes: results from the Look AHEAD trial. Diabetes Care 2011; 34: 2152-2157.
13. Orchard TJ, Temprosa M, Barrett-Connor E, Fowler SE, Goldberg RB, Mather KJ, et al: Long-term effects of the Diabetes Prevention Program interventions on cardiovascular risk factors: a report from the DPP Outcomes Study. Diabet Med 2013; 30: 46-55.
14. Rosenbaum M, Leibel RL: Adaptive thermogenesis in humans. Int J Obes (Lond) 2010; 34(suppl 1):S47-S55.
15. FDA: FDA-approved diabetes medicines. http://www.fda.gov/ForConsumers/ ByAudience/ForPatientAdvocates/DiabetesInfo/ucm294713.htm (accessed January 25, 2013).
16. FDA: High blood pressure - medicines to help you. http://www.fda.gov/ ForConsumers/ByAudience/ForWomen/ucm118594. htm (accessed January 25, 2013).
17. Vilsboll T, Christensen M, Junker AE, Knop FK, Gluud LL: Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ 2012; 344:d7771.
18. Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML, et al: Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377: 1341-1352.
19. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S: Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005; 365: 1389-1397.
20. Fidler MC, Sanchez M, Raether B, Weissman NJ, Smith SR, Shanahan WR, et al: A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab 2011; 96: 3067-3077.
21. Hemo B, Endevelt R, Porath A, Stampfer MJ, Shai I: Adherence to weight loss medications; post-marketing study from HMO pharmacy data of one million individuals. Diabetes Res Clin Pract 2011; 94: 269-275.
22. Johansson K, Neovius K, DeSantis SM, Rossner S, Neovius M: Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis. Obes Rev 2009; 10: 564-575.
23. Schadt EE, Sachs A, Friend S: Embracing complexity, inching closer to reality. Sci STKE 2005; 2005:pe40.
24. Vella A, Camilleri M: Pharmacogenetics: potential role in the treatment of diabetes and obesity. Expert Opin Pharmacother 2008; 9: 1109-1119.
25. Ara R, Blake L, Gray L, Hernandez M, Crowther M, Dunkley A, et al: What is the clinical effectiveness and cost-effectiveness of using drugs in treating obese patients in primary care? A systematic review. Health Technol Assess 2012; 16:III-XIV, 1-195.
26. Wadden TA, Berkowitz RI, Womble LG, Sarwer DB, Phelan S, Cato RK, et al: Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med 2005; 353: 2111-2120.
27. Van Gaal LF, Broom JI, Enzi G, Toplak H: Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study. Orlistat Dose-Ranging Study Group. Eur J Clin Pharmacol 1998; 54: 125-132.
28. Smith SR, Weissman NJ, Anderson CM, Sanchez M, Chuang E, Stubbe S, et al: Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med 2010; 363: 245-256.
29. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J: Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006; 295: 761-775.
30. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use: ICH harmonised tripartite guideline: definitions for genomic biomarkers, pharmacogenomics, pharmacogenetics, genomic data and sample coding categories. E15. 2007 http://www.ich. org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Efficacy/ E15/Step4/E15- Guideline.pdf (accessed January 25, 2013).
31. US Department of Health and Human Services, FDA, CDER, CBER, CDRH: Guidance for industry: clinical pharmacogenomics: premarket evaluation in early-phase clinical studies and recommendations for labeling. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM337169.pdf (accessed August 5, 2013).
32. Muller DJ, Chowdhury NI, Zai CC: The pharmacogenetics of antipsychotic-induced adverse events. Curr Opin Psychiatry 2013; 26: 144-150.
33. Lett TA, Wallace TJ, Chowdhury NI, Tiwari AK, Kennedy JL, Muller DJ: Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications. Mol Psychiatry 2012; 17: 242-266.
34. Finer N: Sibutramine: its mode of action and efficacy. Int J Obes Relat Metab Disord 2002; 26(suppl 4):S29-S33.
35. Halford JC, Harrold JA: 5-HT(2C) receptor agonists and the control of appetite. Handb Exp Pharmacol 2012; 209: 349-356.
36. Siffert W, Forster P, Jockel KH, Mvere DA, Brinkmann B, Naber C, et al: Worldwide ethnic distribution of the G protein beta3 subunit 825T allele and its association with obesity in Caucasian, Chinese, and Black African individuals. J Am Soc Nephrol 1999; 10: 1921-1930.
37. Gutersohn A, Naber C, Muller N, Erbel R, Siffert W: G protein beta3 subunit 825 TT genotype and post-pregnancy weight retention. Lancet 2000; 355: 1240-1241.
38. Hegele RA, Anderson C, Young TK, Connelly PW: G-protein beta3 subunit gene splice variant and body fat distribution in Nunavut Inuit. Genome Res 1999; 9: 972-977.
39. Siffert W, Rosskopf D, Siffert G, Busch S, Moritz A, Erbel R, et al: Association of a human G-protein beta3 subunit variant with hypertension. Nat Genet 1998; 18: 45-48.
40. Hauner H, Meier M, Jockel KH, Frey UH, Siffert W: Prediction of successful weight reduction under sibutramine therapy through genotyping of the G-protein beta3 subunit gene (GNB3) C825T polymorphism. Pharmacogenetics 2003; 13: 453-459.
41. Siffert W, Naber C, Walla M, Ritz E: G protein beta3 subunit 825T allele and its potential association with obesity in hypertensive individuals. J Hypertens 1999; 17: 1095-1098.
42. Grudell AB, Sweetser S, Camilleri M, Eckert DJ, Vazquez-Roque MI, Carlson PJ, et al: A controlled pharmacogenetic trial of sibutramine on weight loss and body composition in obese or overweight adults. Gastroenterology 2008; 135: 1142-1154.
43. Hsiao DJ, Wu LS, Huang SY, Lin E: Weight loss and body fat reduction under sibutramine therapy in obesity with the C825T polymorphism in the GNB3 gene. Pharmacogenet Genomics 2009; 19: 730-733.
44. Peters WR, MacMurry JP, Walker J, Giese RJ Jr, Comings DE: Phenylethanolamine Nmethyltransferase G-148A genetic variant and weight loss in obese women. Obes Res 2003; 11: 415-419.
45. Ji Y, Salavaggione OE, Wang L, Adjei AA, Eckloff B, Wieben ED, et al: Human phenylethanolamine N-methyltransferase pharmacogenomics: gene re-sequencing and functional genomics. J Neurochem 2005; 95: 1766-1776.
46. Vazquez Roque MI, Camilleri M, Clark MM, Tepoel DA, Jensen MD, Graszer KM, et al: Alteration of gastric functions and candidate genes associated with weight reduction in response to sibutramine. Clin Gastroenterol Hepatol 2007; 5: 829-837.
47. Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S, et al: Association of anxietyrelated traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996; 274: 1527-1531.
48. Wellman PJ: Norepinephrine and the control of food intake. Nutrition 2000; 16: 837-842.
49. Kim DM, Yoon SJ, Ahn CW, Cha BS, Lim SK, Kim KR, et al: Sibutramine improves fat distribution and insulin resistance, and increases serum adiponectin levels in Korean obese nondiabetic premenopausal women. Diabetes Res Clin Pract 2004; 66(suppl 1):S139-S144.
50. Siitonen N, Pulkkinen L, Lindstrom J, Kolehmainen M, Eriksson JG, Venojarvi M, et al: Association of ADIPOQ gene variants with body weight, type 2 diabetes and serum adiponectin concentrations: the Finnish Diabetes Prevention Study. BMC Med Genet 2011; 12: 5.
51. Hsiao TJ, Wu LS, Huang SY, Lin E: A common variant in the adiponectin gene on weight loss and body composition under sibutramine therapy in obesity. Clin Pharmacol 2010; 2: 105-110.
52. Luscombe GP, Hopcroft RH, Thomas PC, Buckett WR: The contribution of metabolites to the rapid and potent down-regulation of rat cortical beta-adrenoceptors by the putative antidepressant sibutramine hydrochloride. Neuropharmacology 1989; 28: 129-134.
53. Bae SK, Cao S, Seo KA, Kim H, Kim MJ, Shon JH, et al: Cytochrome P450 2B6 catalyzes the formation of pharmacologically active sibutramine (N-{1-[1-(4-chlorophenyl) cyclobutyl]-3-methylbutyl}-N,N-dimethylamine) metabolites in human liver microsomes. Drug Metab Dispos 2008; 36: 1679-1688.
54. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C: Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 2007; 116: 496-526.
55. Zanger UM, Klein K, Saussele T, Blievernicht J, Hofmann MH, Schwab M: Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance. Pharmacogenomics 2007; 8: 743-759.
56. Kim KA, Song WK, Park JY: Association of CYP2B6, CYP3A5, and CYP2C19 genetic polymorphisms with sibutramine pharmacokinetics in healthy Korean subjects. Clin Pharmacol Ther 2009; 86: 511-518.
57. Chung JY, Jang SB, Lee YJ, Park MS, Park K: Effect of CYP2B6 genotype on the pharmacokinetics of sibutramine and active metabolites in healthy subjects. J Clin Pharmacol 2011; 51: 53-59.
58. Reynolds GP, Templeman LA, Zhang ZJ: The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29: 1021-1028.
59. Werry TD, Loiacono R, Sexton PM, Christopoulos A: RNA editing of the serotonin 5HT2C receptor and its effects on cell signalling, pharmacology and brain function. Pharmacol Ther 2008; 119: 7-23.
60. Yuan X, Yamada K, Ishiyama-Shigemoto S, Koyama W, Nonaka K: Identification of polymorphic loci in the promoter region of the serotonin 5-HT2C receptor gene and their association with obesity and type II diabetes. Diabetologia 2000; 43: 373-376.
61. Chang CJ, Tzeng TF, Liou SS, Chang YS, Liu IM: Kaempferol regulates the lipid-profile in high-fat diet-fed rats through an increase in hepatic PPARalpha levels. Planta Med 2011; 77: 1876-1882.
62. Arranz MJ, Rivera M, Munro JC: Pharmacogenetics of response to antipsychotics in patients with schizophrenia. CNS Drugs 2011; 25: 933-969.
63. Russo P, Strazzullo P, Cappuccio FP, Tregouet DA, Lauria F, Loguercio M, et al: Genetic variations at the endocannabinoid type 1 receptor gene (CNR1) are associated with obesity phenotypes in men. J Clin Endocrinol Metab 2007; 92: 2382-2386.
64. Domschke K, Dannlowski U, Ohrmann P, Lawford B, Bauer J, Kugel H, et al: Cannabinoid receptor 1 (CNR1) gene: impact on antidepressant treatment response and emotion processing in major depression. Eur Neuropsychopharmacol 2008; 18: 751-759.
65. Tokuyama Y, Matsui K, Egashira T, Nozaki O, Ishizuka T, Kanatsuka A: Five missense mutations in glucagon-like peptide 1 receptor gene in Japanese population. Diabetes Res Clin Pract 2004; 66: 63-69.
66. Beinborn M, Worrall CI, McBride EW, Kopin AS: A human glucagon-like peptide-1 receptor polymorphism results in reduced agonist responsiveness. Regul Pept 2005; 130: 1-6.
67. FDA: Highlights of prescribing information. Plavix (clopidogrel bisulfate) tablets. 2011. http://www.accessdata.fda.gov/drugsatfda- docs/label/2011/020839s055lbl.pdf (accessed January 25, 2013).
68. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, et al: Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360: 354-362.
69. Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, Bliden K, et al: Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 2010; 304: 1821-1830.
70. Roses AD: Pharmacogenetics and drug development: the path to safer and more effective drugs. Nat Rev Genet 2004; 5: 645-656.
71. Simpson K, Parker J, Plumer J, Bloom S: CCK, PYY and PP: the control of energy balance. Handb Exp Pharmacol 2012; 209: 209-230.
72. Kissileff HR, Pi-Sunyer FX, Thornton J, Smith GP: C-terminal octapeptide of cholecystokinin decreases food intake in man. Am J Clin Nutr 1981; 34: 154-160.
73. Pi-Sunyer X, Kissileff HR, Thornton J, Smith GP: C-terminal octapeptide of cholecystokinin decreases food intake in obese men. Physiol Behav 1982; 29: 627-630.
74. Gibbs J, Young RC, Smith GP: Cholecystokinin decreases food intake in rats. J Comp Physiol Psychol 1973; 84: 488-495.
75. Roses AD: Stimulation of cholecystokinin-A receptors with Gl181771X: a failed clinical trial that did not test the pharmacogenetic hypothesis for reduction of food intake. Clin Pharmacol Ther 2009; 85: 362-365.
76. Jordan J, Greenway FL, Leiter LA, Li Z, Jacobson P, Murphy K, et al: Stimulation of cholecystokinin- A receptors with GI181771X does not cause weight loss in overweight or obese patients. Clin Pharmacol Ther 2008; 83: 281-287.
77. Orr MS, Goodsaid F, Amur S, Rudman A, Frueh FW: The experience with voluntary genomic data submissions at the FDA and a vision for the future of the voluntary data submission program. Clin Pharmacol Ther 2007; 81: 294-297.
78. Swen JJ, Guchelaar HJ: Just how feasible is pharmacogenetic testing in the primary healthcare setting? Pharmacogenomics 2012; 13: 507-509.
79. Chua EW, Kennedy MA: Current state and future prospects of direct-to-consumer pharmacogenetics. Front Pharmacol 2012; 3: 152.
80. Derosa G, Maffioli P: Efficacy and safety profile evaluation of acarbose alone and in association with other antidiabetic drugs: a systematic review. Clin Ther 2012; 34: 1221-1236.
81. Kang JG, Park CY, Kang JH, Park YW, Park SW: Randomized controlled trial to investigate the effects of a newly developed formulation of phentermine diffuse-controlled release for obesity. Diabetes Obes Metab 2010; 12: 876-882.
82. Cameron F, Whiteside G, McKeage K: Phentermine and topiramate extended release (Qsymia): first global approval. Drugs 2012; 72: 2033-2042.
83. Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A: Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 2007; 370: 1706-1713.